CureVac N.V. (CVAC)
Chart Events
Performance Outlook
| Previous Close | 97.82 |
| Open | 101.42 |
| Bid | 98.50 x 4000 |
| Ask | 98.52 x 800 |
| Day's Range | 97.38 - 101.67 |
| 52 Week Range | 36.15 - 151.80 |
| Volume | 706,562 |
| Avg. Volume | 1,031,985 |
| Market Cap | 18.399B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 92.19 |
- Barrons.com
CureVac Stock Drops on Worries Over Vaccine Trial Delay
Concern has been growing over the German biotech's progress in bringing its Covid-19 vaccine to market.
- Financial Times
The next generation Covid-19 vaccines seeking a slice of the market
BioNTech/Pfizer and Moderna, the pandemic’s mRNA-based vaccine frontrunners, have already booked billions of dollars in revenue, which they are using to boost production, sign new contracts and entrench their positions. Likewise, Oxford/AstraZeneca and Johnson & Johnson have been rolling out their cheaper and easier to transport shots for months, while Chinese and Russian-made vaccines dominate in several markets. Large pharma companies like Sanofi and GSK are hoping to shake off their image as laggards, while start-ups such as Novavax, CureVac and Valneva see opportunities to satisfy unmet needs.
- Simply Wall St.
What Type Of Shareholders Own The Most Number of CureVac N.V. (NASDAQ:CVAC) Shares?
The big shareholder groups in CureVac N.V. ( NASDAQ:CVAC ) have power over the company. Large companies usually have...
